Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640173 | 0.86 | KMT2A (0.49) | KMT2AALOX12NPSR1CTSD | |
| SCHEMBL13640164 | 0.84 | KMT2A (0.43) | KMT2AALOX12NPSR1PARP1 | |
| SCHEMBL8860207 | 0.81 | KMT2A (0.41) | KMT2AALOX12NPSR1 | |
| SCHEMBL13640163 | 0.78 | KMT2A (0.40) | KMT2AALOX12NPSR1 | |
| SCHEMBL13818365 | 0.76 | KMT2A (0.42) | KMT2AALOX12NPSR1 | |
| SCHEMBL13439527 | 0.71 | KMT2A (0.49) | KMT2A | |
| SCHEMBL13640171 | 0.69 | KMT2A (0.50) | KMT2AALOX12NPSR1 | |
| SCHEMBL13640193 | 0.69 | KMT2A (0.37) | KMT2A | |
| SCHEMBL23736270 | 0.67 | KMT2A (0.32) | KMT2A | |
| SCHEMBL9664010 | 0.67 | KMT2A (0.72) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2524925-B1 | LANTHIONINE DERIVATIVE | AJINOMOTO KK (JP) | 2016-08-17 | — | — | EP | disclosed |
| US-8568814-B2 | Lanthionine derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| US-8568814-B2 | Lanthionine derivatives | AJINOMOTO CO., INC. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2524925-A1 | LANTHIONINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2012-11-21 | — | — | EP | disclosed |
| US-20120282386-A1 | LANTHIONINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120282386-A1 | LANTHIONINE DERIVATIVES | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282386-A1 | LANTHIONINE DERIVATIVES | CASR, KCNJ5, CALCR | KMT2A 1148/4885ALOX12 2735/4885NPSR1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.